The estimated Net Worth of Robert Matthew Lutz is at least 1.44 百万$ dollars as of 10 March 2022. Mr. Lutz owns over 24,625 units of Strongbridge Biopharma plc stock worth over 414,750$ and over the last 5 years he sold SBBP stock worth over 8,619$. In addition, he makes 1,016,930$ as Chief Financial Officer at Strongbridge Biopharma plc.
Robert has made over 1 trades of the Strongbridge Biopharma plc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 24,625 units of SBBP stock worth 8,619$ on 10 March 2022.
The largest trade he's ever made was selling 24,625 units of Strongbridge Biopharma plc stock on 10 March 2022 worth over 8,619$. On average, Robert trades about 2,463 units every 0 days since 2020. As of 10 March 2022 he still owns at least 207,375 units of Strongbridge Biopharma plc stock.
You can see the complete history of Mr. Lutz stock trades at the bottom of the page.
Robert Matthew Lutz serves as Chief Financial Officer of the Company. He previously served as our Chief Business Officer from October 2014 to September 2019. Prior to joining the Company, Mr. Lutz worked from December 2004 to April 2014 at Shire Plc, a publicly traded specialty biopharmaceutical company prior to being purchased by Takeda Pharmaceutical Company Ltd., where he most recently served as Vice President and held key leadership positions in the Specialty Pharmaceutical division. Prior to Shire Plc, Mr. Lutz worked in a variety of roles, including Vice President of Finance, for Cinergy Corp., an electric and gas utility company. Mr. Lutz also worked as a Senior Analyst at Alan B. Slifka and Co., a hedge fund, after having started his career at Goldman Sachs Group Inc., where he served as a Financial Analyst in its principal investment area. He holds a B.A. in economics and computer science from Amherst College and an M.B.A. from the Kellogg School of Management.
As the Chief Financial Officer of Strongbridge Biopharma plc, the total compensation of Robert Lutz at Strongbridge Biopharma plc is 1,016,930$. There are 1 executives at Strongbridge Biopharma plc getting paid more, with Frederic Cohen having the highest compensation of 1,093,830$.
Robert Lutz is 51, he's been the Chief Financial Officer of Strongbridge Biopharma plc since 2019. There are 7 older and 2 younger executives at Strongbridge Biopharma plc. The oldest executive at Strongbridge Biopharma plc is David Gill, 65, who is the Independent Director.
Robert's mailing address filed with the SEC is ONE SUMMIT SQUARE,, 1717 LANGHORNE NEWTOWN ROAD, SUITE 300, LANGHORNE, PA, 19047.
Over the last 7 years, insiders at Strongbridge Biopharma plc have traded over 0$ worth of Strongbridge Biopharma plc stock and bought 2,670,648 units worth 8,846,818$ . The most active insiders traders include Associates, L.L.C.Caxton Co...、Garheng Kong、Jeffrey W Sherman. On average, Strongbridge Biopharma plc executives and independent directors trade stock every 89 days with the average trade being worth of 593,478$. The most recent stock trade was executed by David N Gill on 24 September 2020, trading 8,000 units of SBBP stock currently worth 17,040$.
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company's rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.
Strongbridge Biopharma plc executives and other stock owners filed with the SEC include: